Navigation Links
Four of Molecular Medicine's Thought Leaders will Keynote at Cambridge Healthtech Institute's Molecular Medicine Tri-Conference
Date:11/21/2008

Cambridge Healthtech Institute’s (CHI) flagship event, the Molecular Medicine Tri-Conference (February 24-27, 2009) will feature four of molecular medicine’s thought leaders as Plenary Keynotes.

Needham, MA (PRWEB) November 21, 2008 -— Cambridge Healthtech Institute’s (CHI) flagship event, the Molecular Medicine Tri-Conference (February 24-27, 2009) will feature four of molecular medicine’s thought leaders as Plenary Keynotes.

David Ewing Duncan, Chief Correspondent of NPR Talk’s “Biotech Nation” and best-selling Author of “Masterminds”, will offer his insights during his presentation “Brave New Age of Personalized Medicine”, scheduled Thursday, February 26, 2009 at 2:25pm.

Jay M. Tenenbaum, Ph.D, Chairman and Chief Scientist of CollabRx, Inc., will deliver a keynote presentation to discuss “Using Molecular Medicine to do Therapeutic Development in the Network Age”, on Wednesday, February 25, 2009 at 8:55am. Dr. Tenenbaum is a leader in internet commerce and tells the personal and timely story of transforming healthcare and accelerating therapy development through virtual biotechs.

Michael J. Yaszemski, M.D., Ph.D., Brigadier General of the United States Air Force Reserves and Professor of Orthopedic Surgery and Biomedical Engineering, College of Medicine, Mayo Clinic, is breaking new ground in spinal cord nerve regeneration. Dr. Yaszemski’s presentation, “Tissue Engineering Strategies for Musculoskeletal Regenerative Medicine in Civilian and Military Applications”, is on Thursday, February 26, 2009 at 7:30am.

James A. Wells, Ph.D., Professor and Chair of Pharmaceutical Chemistry, and Professor of Cellular & Molecular Pharmacology at the University of California, San Francisco is a pioneer in the hot area of fragment-based screening. Dr. Wells’ Keynote on “Engineering Cells to Death” is scheduled Thursday, February 26, 2009 at 1:40pm.
The Molecular Medicine Tri-Conference keynotes will all be held at the Moscone Convention Center in San Francisco, California.

About the Molecular Medicine Tri-Conference

The Molecular Medicine Tri-Conference is the flagship of event of CHI’s portfolio of 100+ events. Now in its sixteenth year, the Molecular Medicine Tri-Conference is the most comprehensive discovery, diagnostic and development event worldwide. For 2009, the Tri-Conference was developed around the theme of Shaping Future Medicine. Although the term ‘molecular medicine’ has been around for over 20 years, only now do researchers have the means to practice the art. Scientists now have the knowledge at their disposal to improve diagnosis and enhance the efficacy and safety of molecular therapeutics, elements that are essential for future commercial success.

The 2009 conference, you will learn to:

  • Design precision diagnostic tools and identify disease biomarkers (MOLECULAR DIAGNOSTICS)
  • Reduce late-stage attrition through translational biomarkers, more predictive models, and earlier proof-of-concept studies (TRANSLATIONAL MEDICINE)
  • Use genomic, proteomic and pathway information to identify the best drug targets (CANCER PROFILING AND PATHWAYS)
  • Optimize the design of therapeutic agents, including small- and large-molecules, (MEDICINAL CHEMISTRY, PRECLINICAL DEVELOPMENT OF BIOLOGICS)
  • Explore cell-based therapeutics, including the latest advances in stem cell therapies
  • (STEM CELL THERAPIES, PRECLINICAL DEVELOPMENT OF BIOLOGICS)
  • Map intricate pathways and identify drug intervention points
  • (CANCER PROFILING AND PATHWAYS)
  • Develop safer therapeutics that can flourish in the market with reduced chance of adverse events (PRECLINICAL DRUG SAFETY)
  • Generate effective business and diversification strategies to maximize progress with problematic targets and diseases ( EXECUTIVE SUMMIT)
  • Leverage informatics tools and strategies to improve R&D success (IT TRACK)

Last year's event had record-setting attendance that brought together 3000 delegates from over 40 countries. For questions about the Molecular Medicine Tri-Conference, call Cambridge Healthtech Institute at 781-972-5400; or visit www.Tri-Conference.com.

About Cambridge Healthtech Institute

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

www.chicoporate.com

Press Inquiries Please Contact:
Tracey Fielding
Cambridge Healthtech Institute
Ph. (781) 972-5429

###

Read the full story at http://www.prweb.com/releases/2008/11/prweb1651694.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. A new molecular zip code, and a new drug target for Huntingtons disease
2. New knock-out gene model provides molecular clues to breast cancer
3. Molecular probe paints cancer cells in living animals, Stanford researchers find
4. Story ideas from molecular & cellular proteomics
5. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
8. Molecular profiling can accurately predict survival in colon cancer patients
9. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
10. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
11. Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: